RUSSKO and RakFond will support promising R&D in the area of oncology

| By | | News

The scientists involved in various areas of research to find effective solutions against oncological diseases will be able to receive substantial financial support. This financing will be provided in the form of grants by the Foundation for Cancer Research Support (RakFond), a non-government, non-profit organization established to support basic and clinical research in the area of oncology, and the prospects of projects submitted to the competition will be assessed with the help of experts from the Russian Society of Clinical Oncology (RUSSKO).

Russia is among top 10 countries in terms of the number of clinical trials and patients enrolled in them.

“This collaboration allows Russian researchers to co-author the papers published in authoritative scientific journals, and their names appear in reports presented at prestigious oncology congresses,” said one expert.

The collaboration between the Russian Society of Clinical Oncology and RakFond will allow to support the most promising domestic R&D in the area of oncology.

“The applications continue to arrive. The authors set ambitious goals,” said Ilya Timofeev. “For example, a group of researchers wants to assess the role of molecular genetic factors predicting the improved efficacy of surgical intervention in patients with prostate cancer. Another project is aimed at finding biological markers in patients with melanoma, the malignant pigment tumor. Other applicants plan to study the methods for early tumor diagnosis, as well as the options for drug treatment that can significantly reduce the risk of cancer resumption after surgery. The researchers also show interest in new methods of treatment, such as the hyperthermic intraperitoneal chemotherapy, when a heated chemotherapy treatment is delivered directly to the abdomen, or vaccine therapy that stimulates the natural anti-tumor immunity. As we can see, the projects submitted for competition come from a variety of fields in basic and clinical oncology.”